Ron Babecoff

Dr. Ron Babecoff co-founded BiondVax (www.biondvax.com) in 2003, and has led the company as its President and CEO since its inception.  He has guided the company through 5 successful clinical trials (Phase 1/2 and 2), and two ongoing Phase 2 trials in collaboration with the EU and the US NIH towards the Phase 3 for its Universal Flu Vaccine. BiondVax Pharmaceuticals Ltd. is now a public biotech company listed on the NASDAQ: BVXV and TASE: BVXV.

Prior to founding BiondVax, Dr. Babecoff worked for 10 years in marketing and business development in the pharmaceutical industry. As Marketing Manager at Omrix Biopharmaceuticals Ltd., he was responsible for marketing, sales training, public relations, and new product development.  His professional experience ranges from identifying West Nile Fever treatments, building cooperation with the NIH, to forming alliances with leading international pharmaceutical companies.

Dr. Babecoff holds a D.V.M. degree from the University of Liège (ULg), Belgium and a Master of Entrepreneurship and Innovation (MEI) from the Swinburne University of Technology of Melbourne, Australia.

Dr Tamar Ben-YedidiaDr. Tamar Ben-Yedidia has more than 15 years of experience in the field of Immunology, with specific expertise in the development of vaccines. She started her career with Biotechnology General Ltd, BTG (Rehovot), working on the development of a recombinant Hepatitis-B vaccine.

She joined the Weizmann Institute of Science in 1994, and under the auspices of Prof. Ruth Arnon in the Department of Immunology, worked on the design of a peptide-based vaccine against several pathogens and focused on influenza. She continued this work when she left the Weizmann Institute in 2004 to join BiondVax.

Dr. Ben-Yedidia was involved in two European Consortium projects related to evaluation of different approaches for vaccination in which leading laboratories in the field participated. Dr. Ben-Yedidia is often invited to address conferences around the world and is widely published, with numerous refereed articles and invited reviews in various renowned scientific journals.

Dr. Ben-Yedidia received her Ph.D. from the Weizmann Institute after completion of her doctoral thesis entitled “A Peptide-Based Vaccine Against Influenza”.

Shimon Hassin

Dr. Shimon Hassin has over 10 years of experience in Biotechnology, with specific expertise in the development of biopharmaceuticals. Prior to joining the company, Dr. Hassin was co-founder and CEO of Kadimastem, an embryonic stem cell company developing an artificial pancreas for curing Juvenile Diabetes.

Before joining BiondVax, he worked at InSight Biopharmaceuticals, a leading Israeli biotechnology company active in the area of Biogenerics. In his capacity as Head of Process Development he was responsible for the manufacturing of a variety of Biogenerics such as therapeutic antibodies, cytokines and hormones.

Dr. Hassin holds a Ph.D. in Biotechnology from the University of Maryland Biotechnology Institute and was a post-doctoral associate at the University of Bergen Center of Marine Biotechnology.


Uri_Ben_OrMr. Uri Ben-Or brings over a decade of broad experience in corporate finance, accounting, M&A transactions, IPO’s and operations. He provides his services to BiondVax through CFO Direct, a company which he founded and is the Chief Executive Officer.

Prior to founding CFO Direct he served as the VP Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks, where he led all the corporate finance activities, fund raising and legal aspects of the company. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PriceWaterhouseCoopers.

Mr. Ben-Or holds a BA degree in Business from the College of Administration, and a MBA degree from the Bar Ilan University. He is a Certified Public Accountant.

Joshua E Phillipson

Mr. Joshua E. Phillipson brings 15 years of professional experience. He has served as a business management consultant with Accenture in various industries including pharmaceutical, and coordinator for Canada-Israel industrial partnerships. Most recently, Mr. Phillipson was Marketing Manager at BioData Ltd.

With BiondVax, Mr. Phillipson leads Business Development and Marketing efforts.

Mr. Phillipson earned an Honours BSc. from the University of Toronto and a graduate certificate in eBusiness from Centennial College.

View Josh Phillipson's profile on LinkedIn